Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis.
Journal
Journal of clinical psychopharmacology
ISSN: 1533-712X
Titre abrégé: J Clin Psychopharmacol
Pays: United States
ID NLM: 8109496
Informations de publication
Date de publication:
15 May 2024
15 May 2024
Historique:
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
aheadofprint
Résumé
Published studies on the association between lithium use and the decreased risk of major neurocognitive disorders (MNCDs) have shown disparities in their conclusions. We aimed to provide updated evidence of this association. A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Library from inception until August 31, 2023. All the observational studies evaluating the association between lithium use and MNCD risk were eligible for inclusion. Pooled odds ratios (ORs) and 95% prediction intervals were computed using random-effects models. Eight studies with 377,060 subjects were included in the analysis. In the general population on the association between lithium use versus nonuse and dementia, the OR was 0.94 (95% confidence interval [CI] = 0.77-1.24). Further analysis also demonstrated that lithium use was not associated with an increased risk of Alzheimer's disease (OR = 0.69, 95% CI: 0.31-1.65). When the analysis was restricted to individuals with bipolar disorder to reduce the confounding by clinical indication, lithium exposure was also not associated with a decreased risk of MNCD (OR = 0.9, 95% CI = 0.71-1.15). The results of this systematic review and meta-analysis do not support a significant association between lithium use and the risk of MNCD.
Sections du résumé
BACKGROUND
BACKGROUND
Published studies on the association between lithium use and the decreased risk of major neurocognitive disorders (MNCDs) have shown disparities in their conclusions. We aimed to provide updated evidence of this association.
METHODS
METHODS
A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Library from inception until August 31, 2023. All the observational studies evaluating the association between lithium use and MNCD risk were eligible for inclusion. Pooled odds ratios (ORs) and 95% prediction intervals were computed using random-effects models.
RESULTS
RESULTS
Eight studies with 377,060 subjects were included in the analysis. In the general population on the association between lithium use versus nonuse and dementia, the OR was 0.94 (95% confidence interval [CI] = 0.77-1.24). Further analysis also demonstrated that lithium use was not associated with an increased risk of Alzheimer's disease (OR = 0.69, 95% CI: 0.31-1.65). When the analysis was restricted to individuals with bipolar disorder to reduce the confounding by clinical indication, lithium exposure was also not associated with a decreased risk of MNCD (OR = 0.9, 95% CI = 0.71-1.15).
CONCLUSION
CONCLUSIONS
The results of this systematic review and meta-analysis do not support a significant association between lithium use and the risk of MNCD.
Identifiants
pubmed: 38743015
doi: 10.1097/JCP.0000000000001863
pii: 00004714-990000000-00253
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chhatwal JP, Schultz SA, McDade E, et al. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol. 2022;21:140–152.
Stafford J, Chung WT, Sommerlad A, et al. Psychiatric disorders and risk of subsequent dementia: systematic review and meta-analysis of longitudinal studies. Int J Geriatr Psychiatry. 2022;37:10.1002/gps.5711.
Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381:1672–1682.
Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry. 2016;3:646–659.
Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.
Zyoud SH, Waring WS, Sweileh WM, et al. Global research trends in lithium toxicity from 1913 to 2015: a bibliometric analysis. Basic Clin Pharmacol Toxicol. 2017;121:67–73.
Angst J, Gamma A, Gerber-Werder R, et al. Does long-term medication with lithium, clozapine or antidepressants prevent or attenuate dementia in bipolar and depressed patients? Int J Psychiatry Clin Pract. 2007;11:2–8.
Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry. 2007;190:359–360.
Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12:87–94.
Gerhard T, Devanand DP, Huang C, et al. Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Br J Psychiatry. 2015;207:46–51.
Cheng C, Zandi P, Stuart E, et al. Association between lithium use and risk of Alzheimer's disease. J Clin Psychiatry. 2017;78:e139–e145.
Velosa J, Delgado A, Finger E, et al. Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses. Acta Psychiatr Scand. 2020;141:510–521.
Heard DS, Tuttle CSL, Lautenschlager NT, et al. Repurposing proteostasis-modifying drugs to prevent or treat age-related dementia: a systematic review. Front Physiol. 2018;9:1520.
Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits. Aust N Z J Psychiatry. 2014;48:809–818.
Chen S, Underwood BR, Jones PB, et al. Association between lithium use and the incidence of dementia and its subtypes: a retrospective cohort study. PLoS Med. 2022;19:e1003941.
Moon W, Ji E, Shin J, et al. Effect of valproate and lithium on dementia onset risk in bipolar disorder patients. Sci Rep. 2022;12:14142.
Ponzer K, Millischer V, Schalling M, et al. Lithium and risk of cardiovascular disease, dementia and venous thromboembolism. Bipolar Disord. 2023;25:391–401.
Higgins JP. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. Available at: www.cochrane-handbook.org [6 December 2014]. 2014.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–605.
Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1691.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
Lau J, Ioannidis JP, Terrin N, et al. The case of the misleading funnel plot. BMJ. 2006;333:597–600.
Zhang L, Jiang HY, Liu WJ. Anti-seizure medication exposure and the risk of dementia: a meta-analysis of observational studies. Front Neurol. 2023;14:1133816.